Current Status
Not Enrolled
Price
Free
Get Started

Program Director

Jennifer G. Robinson, MD, MPH

Program Director

Raul D Santos, MD, MSc, PhD

Preventing Atherosclerotic Cardiovascular Disease in Patients with Diabetes Mellitus

The IAS recognizes that system-level improvements are needed in the prevention of ASCVD in patients with diabetes and that progress in CVD risk factor control is slowing. Based on US data, only 14% of patients meet targets for all A1C, BP, lipids, and nonsmoking status. 33-49% of patients still do not meet one or several targets for A1C, blood pressure, or lipids. This problem is exacerbated globally as even fewer meet these targets in many low-and middle-income countries.

The purpose of this video series are to provide a better understanding of the evidence-based management of the diabetic patient to reduce ASCVD risk with focused discussion on statins and newer diabetes drugs.

Each section is introducted by general lecture of the clinical prevalence and evidence. The panel will discuss the real world implications and provide practical implemtation advice.

Pre-activity information

Vídeo 3: Farmacoterapias para obesidade e prevenção de DCV

Video 3: Pharmacotherapies for Obesity and CVD Prevention

Vídeo 2: Obesidade e Lesão em Órgãos-Alvo

Video 2: Obesity and Target Organ Damage

Vídeo 1: Epidemiologia da Obesidade e Doença Cardiovascular

Video 1: Epidemiology and Pathophysiology of Obesity and CVD

SESSÃO DE ABERTURA: Manejo da Obesidade – A Perspectiva do Paciente e do Provedor

Video 1: Epidemiology and pathophysiology of obesity and CVD

Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?

Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease

Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD

Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient

Part 1: The History in the Battle of Insulin and Glucagon

Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?

Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares

« » page 1 / 14